# Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)

Study · id `cardio:ct-nct07286747` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07286747](<https://clinicaltrials.gov/study/NCT07286747>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07286747

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 390 participants.

## Technical summary

Registry record NCT07286747. Randomized; triple masking; primary purpose prevention. Start 2026-03-03 (actual); primary completion 2028-05-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 390 participants (planned count; ClinicalTrials.gov record NCT07286747, source copy `cardio:ctgov-nct07286747-2026-09-16`, retrieved 2026-11-18)
- Started: 2026-03-03 (actual) (ClinicalTrials.gov record NCT07286747, source copy `cardio:ctgov-nct07286747-2026-09-16`, retrieved 2026-11-18)
- Primary completion: 2028-05-01 (anticipated) (ClinicalTrials.gov record NCT07286747, source copy `cardio:ctgov-nct07286747-2026-09-16`, retrieved 2026-11-18)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07286747, source copy `cardio:ctgov-nct07286747-2026-09-16`, retrieved 2026-11-18)
- Countries: Germany (ClinicalTrials.gov record NCT07286747, source copy `cardio:ctgov-nct07286747-2026-09-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07286747-2026-09-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)
- Acronym: CONCEPT
- Condition: Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
- Intervention (Drug): controlled-ileal-release nicotinic acid as multiple dose 100 mg/day
- Intervention (Drug): controlled-ileal-release nicotinic acid as multiple dose 200 mg/day
- Intervention (Drug): controlled-ileal-release nicotinic acid as multiple dose placebo
- Lead sponsor: University Hospital Schleswig-Holstein
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry lists this organization as the lead sponsor: University Hospital Schleswig-Holstein (`cardio:org-university-hospital-schleswig-holstein`)

## Provenance

Content hash: a32e0b7656427432952eec63b07e8eb5b5b7e596037ba265176a7b828ba609ae
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
